Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.

Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL.

Clin Cancer Res. 2012 Sep 15;18(18):5099-109. Epub 2012 Jul 27.

2.

Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.

Leandro-García LJ, Inglada-Pérez L, Pita G, Hjerpe E, Leskelä S, Jara C, Mielgo X, González-Neira A, Robledo M, Avall-Lundqvist E, Gréen H, Rodríguez-Antona C.

J Med Genet. 2013 Sep;50(9):599-605. doi: 10.1136/jmedgenet-2012-101466. Epub 2013 Jun 17.

PMID:
23776197
3.

Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.

Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL; Cancer and Leukemia Group B, Cox NJ, Dolan ME.

Clin Cancer Res. 2013 Jan 15;19(2):491-9. doi: 10.1158/1078-0432.CCR-12-2618. Epub 2012 Nov 30.

4.

Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).

Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz DL.

Pharmacogenomics J. 2014 Aug;14(4):336-42. doi: 10.1038/tpj.2014.2. Epub 2014 Feb 11.

5.

Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.

Leandro-García LJ, Leskelä S, Jara C, Gréen H, Avall-Lundqvist E, Wheeler HE, Dolan ME, Inglada-Perez L, Maliszewska A, de Cubas AA, Comino-Méndez I, Mancikova V, Cascón A, Robledo M, Rodríguez-Antona C.

Clin Cancer Res. 2012 Aug 15;18(16):4441-8. Epub 2012 Jun 20.

6.

Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.

Apellániz-Ruiz M, Lee MY, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, García-Estévez L, Sereno M, García-Donás J, Castelo B, Guerra E, Leandro-García LJ, Cascón A, Johansson I, Robledo M, Ingelman-Sundberg M, Rodríguez-Antona C.

Clin Cancer Res. 2015 Jan 15;21(2):322-8. doi: 10.1158/1078-0432.CCR-14-1758. Epub 2014 Nov 14.

7.

Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.

Komatsu M, Wheeler HE, Chung S, Low SK, Wing C, Delaney SM, Gorsic LK, Takahashi A, Kubo M, Kroetz DL, Zhang W, Nakamura Y, Dolan ME.

Clin Cancer Res. 2015 Oct 1;21(19):4337-46. doi: 10.1158/1078-0432.CCR-15-0133. Epub 2015 May 26.

PMID:
26015512
8.

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.

Hertz DL, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, Carey LA, Dees EC, McLeod HL.

Breast Cancer Res Treat. 2014 May;145(1):245-54. doi: 10.1007/s10549-014-2910-1. Epub 2014 Apr 6.

9.

Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.

Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Lu X, Winick NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui CH, Dolan ME, Relling MV, Evans WE.

JAMA. 2015 Feb 24;313(8):815-23. doi: 10.1001/jama.2015.0894.

10.

Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial.

Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, Hashemzade S, Asghari Jafarabadi M, Montazeri V, Keshavarz SA, Darabi M.

BMC Cancer. 2012 Aug 15;12:355.

11.

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.

Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC.

Ann Oncol. 2013 Jun;24(6):1472-8. doi: 10.1093/annonc/mdt018. Epub 2013 Feb 14.

12.

Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy.

Azoulay D, Leibovici A, Sharoni R, Shaoul E, Gross B, Braester A, Goldberg H.

Breast Cancer Res Treat. 2015 Oct;153(3):703-4. doi: 10.1007/s10549-015-3546-5. Epub 2015 Aug 14. No abstract available.

PMID:
26272744
13.

Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.

Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, Vallier AL, Hiller L, Burns R, Jones L, Bowden SJ, Dunn JA, Poole CJ, Caldas C, Pharoah PP, Earl HM.

Clin Cancer Res. 2014 May 1;20(9):2466-75. doi: 10.1158/1078-0432.CCR-13-3232. Epub 2014 Mar 5.

14.

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH.

Support Care Cancer. 2009 Aug;17(8):1071-80. doi: 10.1007/s00520-008-0550-x. Epub 2008 Dec 17.

PMID:
19089463
15.

Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.

Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K.

Clin Cancer Res. 2005 Jul 1;11(13):4843-50.

16.

Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.

Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL.

Cancer. 2012 Oct 15;118(20):5171-8. doi: 10.1002/cncr.27489. Epub 2012 Mar 13.

17.

Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance).

Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, Ruddy KJ, Pleticha J, Lynch CA, Behrens RJ, Züchner S, Loprinzi CL, Beutler AS.

J Neurol Sci. 2015 Oct 15;357(1-2):35-40. doi: 10.1016/j.jns.2015.06.056. Epub 2015 Jun 27.

PMID:
26143528
18.

Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy.

Zhang H, Boyette-Davis JA, Kosturakis AK, Li Y, Yoon SY, Walters ET, Dougherty PM.

J Pain. 2013 Oct;14(10):1031-44. doi: 10.1016/j.jpain.2013.03.012. Epub 2013 May 31.

19.

Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.

Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S.

Eur J Cancer. 2006 Nov;42(17):2893-6. Epub 2006 Sep 6.

20.

Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.

Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S.

J Pain. 2009 Nov;10(11):1146-50. doi: 10.1016/j.jpain.2009.04.006.

Items per page

Supplemental Content

Write to the Help Desk